Also known as: locally advanced rectal cancer, rectal cancers
Rectal cancer is a malignant neoplasm arising in the rectum, most commonly adenocarcinoma, and is often managed with multimodality treatment including surgery, radiation, and systemic therapy.
At ESMO GI 2026, experts presented the EBAI framework classifying AI-based biomarkers into three validation tiers. Clinical data showed AI detecting MSI with 96-98% sensitivity and MRI-guided brachytherapy improving recurrence-free survival.
AI identified rectal cancer patients who benefit from adding irinotecan to chemoradiotherapy, cutting recurrence and death risk. Separate research finds most online AI-cancer information is low quality and too complex for patients.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
Studies in gastroesophageal and locally advanced rectal cancers linked dynamic ctDNA monitoring to treatment response and prognosis. MRD clearance, more than 90% ctDNA declines, and early ctDNA clearance were associated with better outcomes.
A rectal cancer study found hypofractionated radiotherapy increased ISG15+MHC-I+ neutrophils with antigen-presenting capabilities. The report linked the effect to IFN-α/NOD1 signaling and improved anti-PD-1 responses in models.
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780305 |
Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria |
NOT_YET_RECRUITING | |
| NCT07774754 |
Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07764120 |
Quality of Life of Patients After Rectal Cancer Resection . |
NOT_YET_RECRUITING | |
| NCT07761169 |
Randomized Controlled Trial of the SurgDiff Model for Predicting Surgical Difficulty to Help Choose Approach in Mid-Low Rectal Cancer |
NOT_YET_RECRUITING | NA |
| NCT07736131 |
Learning Curve of SILS in CRC |
COMPLETED | |
| NCT07732894 |
Aerobic Exercise and Guided Imagery in Low Anterior Resection Syndrome |
RECRUITING | NA |
| NCT07711509 |
Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Rectal Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT07695519 |
SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer |
NOT_YET_RECRUITING | |
| NCT07669298 |
Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer |
RECRUITING | NA |
| NCT07646639 |
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC |
RECRUITING | PHASE2 |
